ADAM metallopeptidase domain 28Genealiases: ADAM 28 · MDC-L · MDCL · eMDC II · eMDCII
Q-omics provides the consensus-scored ADAM28 profile across patient tissues and cancer cell-line models. ADAM28 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ADAM28 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ADAM28 protein abundance shows 29,269 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where ADAM28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAM28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAM28 survival associations across molecular data types. ADAM28 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAM28 RNA expression–survival associations across cancer types. High ADAM28 expression shows unfavorable associations in UVM and LGG, but favorable associations in SKCM, HNSC, UCEC and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ADAM28 RNA expression.
This table summarizes ADAM28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ADAM28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAM28 shows lower tumor expression in COAD and KICH and higher tumor expression in KIRC, LUAD, CHOL and UCEC. The KIRC box plot shows higher ADAM28 RNA expression in tumor versus normal tissue (log2 FC = +1.355, t-test p < 0.001).
This table shows molecular features associated with ADAM28 in patient tissues and cancer cell lines. In patient samples, ADAM28 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAM28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
